Literature DB >> 10025788

Increased CSF F2-isoprostane concentration in probable AD.

T J Montine1, M F Beal, M E Cudkowicz, H O'Donnell, R A Margolin, L McFarland, A F Bachrach, W E Zackert, L J Roberts, J D Morrow.   

Abstract

OBJECTIVE: To quantify F2-isoprostane levels in CSF obtained from the lumbar cistern of patients with AD, ALS, and controls.
BACKGROUND: Studies of human postmortem tissue and experimental models have suggested a role for oxidative damage in the pathogenesis of several neurodegenerative diseases, especially AD and ALS. F2-isoprostanes are exclusive products of free-radical-mediated peroxidation of arachidonic acid that have been widely used as quantitative biomarkers of lipid peroxidation in vivo in humans. Recently, we showed that F2-isoprostane concentrations are significantly elevated in CSF obtained postmortem from the lateral ventricles of patients with definite AD compared with controls.
METHODS: F2-isoprostanes were quantified by gas chromatography/negative ion chemical ionization mass spectrometry.
RESULTS: CSF F2-isoprostanes were increased significantly in patients with probable AD, but not in ALS patients, compared with controls.
CONCLUSIONS: Increased CSF F2-isoprostanes are not an inevitable consequence of neurodegeneration and suggest that increased brain oxidative damage may occur early in the course of AD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025788     DOI: 10.1212/wnl.52.3.562

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  57 in total

1.  Human, but not bovine, oxidized cerebral spinal fluid lipoproteins disrupt neuronal microtubules.

Authors:  M D Neely; L L Swift; T J Montine
Journal:  Lipids       Date:  2000-11       Impact factor: 1.880

2.  Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo.

Authors:  C N Bassett; M D Neely; K R Sidell; W R Markesbery; L L Swift; T J Montine
Journal:  Lipids       Date:  1999-12       Impact factor: 1.880

3.  CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

Authors:  Norbert Zilka; Miroslava Korenova; Branislav Kovacech; Khalid Iqbal; Michal Novak
Journal:  Acta Neuropathol       Date:  2010-04-09       Impact factor: 17.088

Review 4.  Oxidative imbalance in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-Gon Lee; Gemma Casadesus; Jesus Avila; Kelly Drew; George Perry; Mark A Smith
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

5.  Plasma F2-isoprostane level and cognitive function over eight years in non-demented older adults: Findings from the Health ABC Study.

Authors:  A J Fiocco; A M Kanaya; K M Lindquist; T B Harris; S Satterfield; E M Simonsick; L Kuller; C Rosano; K Yaffe
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-09-25       Impact factor: 4.006

Review 6.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

8.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

Review 9.  Lipidomic analysis of cerebrospinal fluid by mass spectrometry-based methods.

Authors:  Benoit Colsch; Alexandre Seyer; Samia Boudah; Christophe Junot
Journal:  J Inherit Metab Dis       Date:  2014-12-09       Impact factor: 4.982

Review 10.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.